Philadelphia, PA - September 22, 2009
ACR Image Metrix™, an imaging contract research organization (CRO), exceeded its goals by initiating projects for over 30 pharmaceutical, biotechnology and medical device companies through its second full year of operation. Many of these awarded projects were “repeat” business from their existing client base. ACR Image Metrix, a leader in imaging trial design, techniques, data extraction, management and analysis, was launched as a for-profit division of the American College of Radiology® (ACR) in 2007 with profits being reinvested into the ACR Clinical Research Center.
“The value of imaging in clinical trials is evident and is paving the way for better integration of molecular, functional and volumetric imaging in the drug discovery process," said Mike Morales, ACR Image Metrix general manager.
“This year we also expanded our office space and core imaging laboratories, allowing us greater capacity to handle larger global research projects,” said Veronique Cardon, ACR Image Metrix director of business development.
The 10,000 square-foot facility also includes two learning laboratories designed for researchers to acquire the knowledge and skills needed to perform advanced imaging techniques. The core imaging laboratory has evolved to include a focus on the increasing challenges associated with advanced imaging capabilities in imaging clinical research today. These advanced imaging techniques include DCE-MRI, diffusion weighted/tensor imaging, FDG and FLT-PET and many more. In addition, ACR Image Metrix also offers services to the medical device industry in conducting clinical research to secure regulatory approvals for their new devices and software products such as CAD (computer aided detection).
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.